Fibromyalgia Treatment Market Size & Share, by Drug Class (Antidepressants, Antiepileptic, Muscle Relaxants); Type (Symptomatic Treatment, Targeted Treatment); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2033

  • Report ID: 4467
  • Published Date: Feb 27, 2023
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2023-2033

Fibromyalgia Treatment Market size is estimated to reach USD 536 million by the end of 2033, growing at a CAGR of 9% during the forecast period, i.e., 2023-2033. In the year 2022, the industry size of fibromyalgia treatment was over USD 190 million. The growth of the market is primarily ascribed to the worldwide escalating load of chronic pain. Fibromyalgia, according to researchers, increases painful sensations by altering how the brain and spinal cord receive painful and non-painful impulses. As per the World Health Organization (WHO), nearly 1.71 billion people around the world have been suffering from musculoskeletal disorders.

Fibromyalgia, commonly known as fibromyalgia syndrome, is a severe neurologic condition that results in immense pain throughout the body. This condition affects people physically, intellectually, and socially and causes exhaustion, musculoskeletal pain, and localized discomfort. Furthermore, there are only a few drugs, such as milnacipran, and pregabalin which are prescribed for fibromyalgia treatment. Globally rising occurrence of musculoskeletal disorder is leading to increased chances of fibromyalgia. According to the National Fibromyalgia Association, fibromyalgia affects an estimated 10 million people in the United States.


Fibromyalgia Treatment Market
Get more information on this report: Request Free Sample PDF


Fibromyalgia Treatment Market: Key Insights

Base Year

2022

Forecast Year

2023-2033

CAGR

~9%

Base Year Market Size (2022)

~ USD 190 Million

Forecast Year Market Size (2033)

~ USD 536 Million

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Fibromyalgia Treatment Sector: Growth Drivers and Challenges

Market-Growth-Drivers

Growth Drivers

  • Growing Prevalence of Fibromyalgia Treatment- There are numerous factors that is expected to drive the global fibromyalgia treatment market’s growth. However, the primary factor that is anticipated to grow the market is the rise in fibromyalgia globally. According to the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), 5 million Americans who are 18 years of age or older have fibromyalgia, and females make up between 80 and 90 percent of fibromyalgia patients. Additionally, there were nearly 1.75 million adults in England and Wales with fibromyalgia as of 2019.
  • Increasing Government Initiatives - It is predicted that the market will increase as a result of the growing government initiatives that provide manufacturers and medical practitioners with guidance regarding fibromyalgia. For instance, the European League Against Rheumatism (EULAR) advised against using non-steroidal anti-inflammatory medicines (NSAID) to treat fibromyalgia in their 2016 recommendations. According to estimates, these policies will assist the affected population to manage their fibromyalgia and raise awareness of the condition.
  • Worldwide Growing Incidences of Road Accidents - Road accidents are the most dreadful thing that happens to a road user, even though they occur quite frequently. The majority of fatal accidents are caused by excessive speeding, the use of alcohol, or any psychoactive substance or drug. These factors raise the risk of road accidents resulting in death or serious injury. Many times, the surviving person phases long-term disability or severe pain which turns into fibromyalgia disorder over time. Thus, increasing road accidents lead to the growing prevalence of fibromyalgia disorder. According to the World Health Organization statistics, road accidents claim the lives of around 1.3 million people every year across the globe. There are an additional 20 to 50 million people who sustain non-fatal injuries, many of whom proceed to suffer disabilities.
  • Surge in Novel Drug Development – Chronic illness fibromyalgia substantially limits patients' ability to engage in typical social and professional activities and makes it difficult to maintain relationships with friends, family, and co-workers. The full spectrum of pain, tiredness, sleep disturbances, and depression symptoms is not completely addressed by any of the medicines currently available. However, the pharmaceutical industry's expanding endeavors have led to the launch of new experimental treatments by deploying novel drug delivery systems, a novel combination of already-approved drugs, as well as inquiries into the potential for using drugs already being prescribed for other ailments. For instance, in 2021, following a pre-NDA meeting with the US Food and Drug Administration, Axsome Therapeutics, Inc., which develops novel therapies for the treatment of central nervous system (CNS) disorders, announced its decision to submit a New Drug Application (NDA) for AXS-14 for the treatment of fibromyalgia (FDA). AXS-14 (esreboxetine) is a new oral, norepinephrine reuptake inhibitor that is both potent and selective.
  • Worldwide Boost in the Population of People Above 60- As per the data released by the World Health Organization, the worldwide population of people aged 60 and over is projected to propagate from 1 billion in 2020 to 1.4 billion by 2030. By 2050, the world's population of people aged 60 and above is anticipated to double by 2.1 billion.

Challenges

  • High Adoption of Generic Drugs Only three medications are currently specifically licensed for the treatment of fibromyalgia. As a result, off-label medications and generic antidepressants are being used more frequently to treat the disease's symptoms. Therefore, it is expected to hamper the market’s growth.
  • Side Effects Associated with the Use of Fibromyalgia Drugs - Suicidal ideation may be increased in some persons by certain medications. Nausea, headache, exhaustion, high blood pressure, racing heart, excessive sweating, agitation, cholesterol, triglyceride increase, and tremor are all possible side effects.
  • Stringent Regulations of Government


Fibromyalgia Treatment Segmentation

Drug Class (Antidepressants, Antiepileptic, Muscle Relaxants)

The global fibromyalgia treatment market is segmented and analyzed for demand and supply by drug class into antidepressants, antiepileptics, muscle relaxants, and others. Out of the these, types of drug-class antiepileptics segment is estimated to gain the largest market share over the projected time frame. Anticonvulsants, usually referred to as antiepileptic medications, are frequently prescribed to treat epilepsy, and on the other hand, they have also been used to treat fibromyalgia. The FDA has approved the antiepileptic drug pregabalin for the treatment of fibromyalgia. Pregabalin blocks the release of substances P, norepinephrine, and glutamate, which may significantly help fibromyalgia patients feel less pain. Depending on the patient's creatinine clearance, pregabalin must be begun at 75 mg twice daily and gradually increased to 225 mg twice daily. Total daily doses of 300 mg, 450 mg, or 600 mg can lessen pain by more than 30% if the patient can bear the side effects of drowsiness, dry mouth, added weight, and oedema. The market for antidepressants, is anticipated to hold the second largest share over the forecast period. The signs of depression may be lessened with the aid of antidepressants. Additionally, they can help in the treatment of seasonal affective disorder and social anxiety disorder. There is growing evidence that, to a limited extent, antidepressants are effective therapies for fibromyalgia. Antidepressants change specific neurotransmitters in the brain, and these same neurotransmitters play a role in fibromyalgia. One of the most popular forms of treatment is amitriptyline and other tricyclic antidepressants (TCAs). Newer antidepressants have undergone thorough fibromyalgia testing since they are better tolerated than tricyclics. Instead of acting as an antidepressant, cyclobenzaprine, a tricyclic substance that varies from amitriptyline only by one double bond, relaxes the muscles.

Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

The global fibromyalgia treatment market is also segmented and analyzed for distribution by distribution into retail pharmacies, hospital pharmacies, and online pharmacies. Amongst these three segments, the retail pharmacies segment is expected to garner a significant share. Any pharmacy that dispenses, stocks, or sells prescription drugs to the general public is considered retail pharmacy. Any consumer can pick up their medication at a retail pharmacy without first acquiring a prescription. Moreover, the customers have direct contact with the retailer. A reputable company that sells medicines and related goods is a retail pharmacy. Since hospitalization is not always necessary for fibromyalgia therapy, retail pharmacies are expected to gain market share during the anticipated period. Hospital pharmacies, which were expected to expand at the greatest CAGR, were the second-largest market in 2021. Integrated into the care of a medical facility is the subsection of pharmacy known as a hospital pharmacy. These include residential care institutions, hospitals, outpatient clinics, drug addiction treatment centers, poison control centers, and drug resource centers. The job involves choosing, preparing, storing, compounding, and dispensing drugs for patients in a medical setting. Hospital pharmacies' primary responsibility in patient care is risk management.

Our in-depth analysis of the global market includes the following segments:

               By Drug Class

  • Antidepressants
  • Antiepileptic
  • Muscle Relaxants
  •  Others

                By Type

  • Symptomatic Treatment
  • Targeted Treatment

                By Distribution

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Fibromyalgia Treatment Industry - Regional Synopsis

APAC Market Statistics

The Asia-Pacific market is anticipated to increase steadily throughout the course of the forecast period. Aspects such as the growing number of fibromyalgia patients, along with rising healthcare spending and developing healthcare infrastructure, are predicted to boost the market growth in the Asia Pacific.

North American Market Forecast

The North America fibromyalgia treatment market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2033. It is backed by the radically increasing prevalence of fibromyalgia, and the rising awareness among people regarding fibromyalgia in the region. As per the Centers for Disease Control and Prevention, fibromyalgia affects approximately 4 million adults in the United States, accounting for approximately 2% of the adult population.

Get more information on this report: Request Free Sample PDF

Companies Dominating the Fibromyalgia Treatment Landscape

top-features-companies
    • Pfizer Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • AbbVie Inc.
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd.
    • GlaxoSmithKline plc
    •  Aptinyx Inc.
    • Tonix Pharmaceuticals Holding Corp.
    • Virios Therapeutics

In-the-news

In The News

  • Aptinyx Inc. declared the completion of the enrolment of 305 patients in the current Phase 2b study of NYX-2925 in fibromyalgia. NYX-2925 is being studied in 305 patients with fibromyalgia in a randomized, double-blind, placebo-controlled Phase 2 study.

  • Astellas Pharma Inc. has acquired bioelectronics start-up company Iota Biosciences, Inc. Astellas' Rx+ projects are estimated to accelerate in light of this acquisition.


Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 4467
  • Published Date: Feb 27, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Worldwide growing incidences of road accidents, surge in post-traumatic stress disorder (PTSD), and worldwide boost in geriatric population are some major factors driving the growth of the market.

The market is anticipated to attain a CAGR of 9% over the forecast period, i.e., 2023-2033.

Side effects associated with the use of fibromyalgia drugs, high adoption of generic drugs, and stringent regulations of government are estimated to hamper the market growth.

The market in North America is projected to hold the largest market share by the end of 2033 and provide more business opportunities in the future.

The major players in the market are Pfizer Inc., AbbVie Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Aptinyx Inc., Tonix Pharmaceuticals Holding Corp., Virios Therapeutics, Inc., and others.

The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by drug class, type, distribution channel, and by region.

The antiepileptic segment is anticipated to garner the largest market size by the end of 2033 and display significant growth opportunities.
Fibromyalgia Treatment Market Report Scope
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying